The Scientist

» monoclonal antibodies

Most Recent

image: Cautious Optimism About ZMapp Trial

Cautious Optimism About ZMapp Trial

By | February 25, 2016

The Ebola drug increased survival in a small study, but the effect was not statistically significant.

0 Comments

image: Single Antibody Protects Macaques from Ebola

Single Antibody Protects Macaques from Ebola

By | February 25, 2016

The “just right” binding properties of a monoclonal antibody from an Ebolavirus survivor help it neutralize the virus.

0 Comments

image: In Situ Antibodies

In Situ Antibodies

By | February 2, 2016

Compared with systemic injections, localized antibody therapies may be more effective for some indications.

2 Comments

image: Antibody Alternatives

Antibody Alternatives

By and | February 1, 2016

Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.

2 Comments

image: Exercises for Your Abs

Exercises for Your Abs

By | February 1, 2016

Companies make the antibodies, but it’s up to you to make sure they work in your experiments.

3 Comments

image: Building Better Reagents

Building Better Reagents

By and | February 1, 2016

Facing problems of inconsistent, time-consuming, and costly antibody production, some researchers are turning to alternatives to target specific proteins of interest, in the lab and in the clinic.

0 Comments

Some antibodies designed to eliminate the plaques prominent in Alzheimer’s disease can aggravate neuronal hyperactivity in mice.

1 Comment

image: Two-Faced Proteins May Tackle HIV Reservoirs

Two-Faced Proteins May Tackle HIV Reservoirs

By | October 21, 2015

Researchers design antibody-like proteins to awaken and destroy HIV holdouts.

0 Comments

image: Novartis Buys Rights to GSK MS Drug for $1 Billion

Novartis Buys Rights to GSK MS Drug for $1 Billion

By | August 24, 2015

The multiple sclerosis treatment has yet to be tested in Phase 3 clinical trials.

0 Comments

image: Moving MERS Therapies Forward

Moving MERS Therapies Forward

By | July 28, 2015

Scientists wonder whether they can obtain the resources to test experimental vaccines and treatments in humans.

3 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

  4. Another DNA Vaccine for Zika Shows Promise
RayBiotech